Strong oncology CROs pair realistic investigator relationships with workable startup and enrollment expectations.
Oncology CRO guide
Best CRO for oncology: shortlist for sites, biomarkers, and delivery discipline.
The best CRO for oncology is the one that matches the actual oncology programme: tumour type, phase, biomarker strategy, region mix, and the level of sponsor control needed over a complex study.
Oncology trials become fragile quickly when sample flow, pathology, and data handoffs sit on weak vendor architecture.
Sponsors should know who will run the programme, who owns escalation, and how stable that team really is.
Solid tumour, haematology, rare oncology, and biomarker-heavy trials often need different shortlist logic.
What to test
Ask whether the CRO can actually support the oncology operating model, not just sell into it.
- Indication and phase depth that matches the brief.
- Realistic assumptions on sites, activation, and enrollment.
- Strength of imaging, pathology, biomarker, and lab coordination.
Where shortlists fail
Oncology shortlists weaken when sponsors over-index on prestige, legacy relationships, or broad capability claims.
- Choosing scale when a tighter specialist fit would be more controllable.
- Underestimating biomarker and sample-flow risk.
- Assuming the sales pitch reflects the actual delivery team.
Use CVC
Compare oncology-facing CROs with more structure.
Use the vendor directory to build an oncology shortlist, then use sponsor support if the final process needs more pressure-testing.
Related guide
Best CRO for biotech
If the question is broader than oncology alone, start with the biotech CRO guide and then narrow by indication, phase, and delivery model.
Read the biotech CRO guide